OBJECTIVES The aim of this study was to perform a collaborative meta-analysis of published and unpublished qualityof-life, morbidity, and mortality data from randomized controlled trial comparisons of radiofrequency ablation (RFA) and antiarrhythmic drug therapy (AAD) in symptomatic atrial fibrillation.
T he optimal therapeutic approach for atrial fibrillation (AF) is still debated. A beneficial effect of radiofrequency ablation (RFA) on quality of life (QoL) has been suggested by several studies (1, 2) , but it is unclear whether the effect of RFA on QoL is sustained, because long-term followup data have been limited (3) . Also, previous retrospective analyses have demonstrated conflicting results with regard to stroke and hospitalization risks with RFA and antiarrhythmic drug therapy (AAD) (4, 5) , and no randomized controlled trials (RCTs) have been sufficiently powered to address these issues. Finally, given the demonstrated superiority of RFA over AAD in rhythm control, and the potential ensuing decreased need for anticoagulation (6, 7) , long-term bleeding should theoretically be less frequent with an RFA strategy. However, this remains unproved.
Meta-analyses have demonstrated the superiority of RFA in maintaining sinus rhythm compared with AAD (8) (9) (10) (11) (12) (13) (14) (15) (16) . However, only 1 study analyzed limited published QoL data in nonstandardized scales and demonstrated superiority of RFA, without addressing the longevity of this effect. Three meta-analyses assessed the safety of RFA and AAD and considered all adverse events related to the interventions collectively, ranging from minor events to death, without specifically focusing on clinically important outcomes such as stroke and bleeding (8, 11, 14) . Only 1 metaanalysis synthesized limited published data from 3 RCTs on the risk for cardiovascular hospitalization and demonstrated favorable RFA effects (15) . Also, a recent meta-analysis of 3 studies assessed the safety and effectiveness of RFA only as first-line treatment (16) .
No meta-analysis has been previously aimed at addressing specifically the long-term risks for stroke, bleeding, or death with RFA and AAD strategies. ELIGIBILITY OF STUDIES. We considered trials that randomly assigned patients with paroxysmal or persistent AF to any type of RFA versus AAD. Trials were eligible regardless of whether RFA was used as first-line therapy or not. Studies examining RFA versus AAD in patients with AF and heart failure were excluded because of the distinct QoL and overall prognostic characteristics of this patient population.
We also excluded trials comparing the 2 modes of therapy following failure of previous ablation attempt, trials comparing different ablation techniques without medical management arms, trials evaluating RFA versus rate control, and trials comparing AAD with no AAD after ablation.
DATA COLLECTION AND ENDPOINTS OF INTEREST.
For each eligible RCT, we documented general study Table 1 ). None of the included trials was at high risk for bias in more than 1 of the evaluated areas. However, potential risks were frequently unclear (Online Table 1 By intention to treat, RFA was significantly more successful than AAD for arrhythmia control in all trials ( Table 2) .
Siontis et al. Values are n (%). *By the end of follow-up; even after occurrence of the primary outcome. †Three patients underwent RFA during the blanking period. ‡According to each study's definition of treatment success. §One patient underwent repeat RFA during the blanking period.
Abbreviations as in Table 1 .
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arms, respectively. Heterogeneity was large (I 2 ¼ 91%;
95% CI: 84% to 95%), and by random effects the summary RR was 0.50 (95% CI: 0.22 to 1.16) (Online 
STROKE, BLEEDING, AND ALL-CAUSE MORTALITY.
There were 7 strokes in the RFA arms and none in the control arms (follow-up 6 to 48 months among trials).
Five of the RFA strokes were related to the ablation procedure (periprocedural stroke risk 0.3%), and 4 occurred in the TTOP-AF study, which used the phased RFA system (3 strokes happened within the Eleven studies had available bleeding data with a total of 22 events, 13 in the RFA and 9 in the control arms. There was no significant difference between SMD ¼ standardized mean difference.
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